Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
| ▸ | NNMT | P40261 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | TET3 | O43151 | 1/20 | 0.39 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.39 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.39 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.39 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 2/20 | 0.39 |
| ▸ | SELL | P14151 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21874173 | 0.95 | KMT2A (0.49) | KMT2AMEN1TSHRALDH1A1AKR1C1 | |
| SCHEMBL3258917 | 0.94 | NNMT (0.46) | KMT2AMEN1TSHRALDH1A1AKR1C1 | |
| SCHEMBL21873938 | 0.82 | ALDH1A1 (0.46) | KMT2AMEN1ALDH1A1NNMTMKNK1 | |
| SCHEMBL6177725 | 0.80 | NNMT (0.53) | KMT2AMEN1ALDH1A1NNMTMKNK1 | |
| SCHEMBL29730575 | 0.80 | NNMT (0.53) | KMT2AMEN1ALDH1A1NNMTMKNK1 | |
| SCHEMBL3007679 | 0.80 | AKR1C1 (0.44) | KMT2AMEN1TSHRALDH1A1AKR1C1 | |
| SCHEMBL12850050 | 0.78 | NNMT (0.39) | KMT2AMEN1ALDH1A1NNMTMKNK1 | |
| SCHEMBL21964347 | 0.78 | HSD11B1 (0.56) | KMT2AMEN1TSHRALDH1A1EP300 | |
| SCHEMBL23231746 | 0.78 | NNMT (0.41) | KMT2AMEN1ALDH1A1NNMTMKNK1 | |
| SCHEMBL21874594 | 0.76 | AKR1C1 (0.49) | KMT2AMEN1TSHRALDH1A1AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230027952-A1 | NOVEL SALTS OF INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | InventisBio Co., Ltd. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO LLC (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2021104186-A1 | NOVEL SALTS OF INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | InventisBio Co., Ltd. (CN) | 2021-06-03 | — | — | WO | disclosed |
| WO-2017139414-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | INVENTISBIO INC. (KY) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338373-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | KMT2A 506/4885MEN1 1500/4885TSHR 3848/4885 |
| US-20230027952-A1 | NOVEL SALTS OF INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, KYNU | KMT2A 1577/4885MEN1 1721/4885TSHR 2886/4885 |
| US-20220054486-A1 | INHIBITOR OF INDOLEAMINE-2,3-DIOXYGENASE (IDO) | IDO1, IDO2, INMT | KMT2A 506/4885MEN1 1500/4885TSHR 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.